FDA Plans Ultra-Fast Review of Three Psychedelics for Depression, PTSD

(MedPage Today) — The FDA announced Friday that it will offer an ultra-rapid review of three psychedelic drugs in development for difficult-to-treat forms of depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward…